Medical application of kedilao extract

Abstract

The invention relates to the technical field of medicines, in particular to medical application of a kedilao extract. The invention discloses the medical application of the kedilao extract for preventing, relieving and / or treating allergic asthma for the first time. The kedilao extract can reduce inflammatory cell infiltration, improve airway structure damage and improve airway wall thickening; the secretion of Th1 type cytokines is improved, the secretion of Th2 type cytokines is reduced, and the effect of obviously relieving asthma is achieved. Compared with an existing medicine for treating asthma, the kedilao extract is safer, more effective, milder and lasting, the action mechanism is multi-target and multi-effect, and the situation that a single-target medicine generates strong drug resistance is avoided. Therefore, the kdilao extract has considerable development and utilization values in the aspect of relieving and treating the allergic asthma.

Description

Technical Field

[0001] The invention relates to the technical field of medicines, and in particular to the medical use of a kediola extract. Background Art

[0002] Allergic asthma (ASS) is a refractory respiratory disease with clinical manifestations such as recurrent wheezing, shortness of breath, chest tightness or cough, and is mainly characterized by inflammatory cell infiltration, airway remodeling, and airway hyperresponsiveness. Allergic asthma is the most common subtype of asthma, mainly characterized by type 2 T helper cell (T helper cell 2, Th2) immune response causing eosinophilic granulocyte (eosnophils, EOS) airway inflammation and IgE-mediated mast cell degranulation. Th1 / Th2 cell imbalance is one of the pathogenesis of asthma, among which type II cytokines are the hallmark features of promoting the disease. Under the stimulation of allergens, Th1 and Th2 cells show a mutually restrictive relationship. Th1 cells mainly secrete interferon-γ (INF-γ), interleukin 2 (IL-2), and transforming growth factor TNF-β, while Th2 cells mainly secrete IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13. At present, the main drugs for treating ASS include glucocorticoids, omalizumab, leukotriene receptor antagonists, mast cell stabilizers, etc. The above drugs have clear efficacy, but their effects are limited and their adverse reactions are obvious. Long-term use will reduce the patient's tolerance and increase the patient's economic burden. However, natural medicines have the advantages of low toxicity and side effects and multi-target treatment, and have become an important source of drugs for treating asthma and relieving inflammation.

[0003] Kedi Lao is the mature fruit of Elaeocarpus braceanus Watt ex CBClarke., a plant of the Elaeocarpus family. It is also known as wild peach and kelilao. It is mainly distributed in the western and southwestern regions of Yunnan and the eastern region of Tibet in my country. It is also distributed in India, Myanmar, Laos, Vietnam and other countries. Kedi Lao has a sour and astringent taste, bitter and sweet. It is a traditional medicinal plant of the Lhoba people in Medog County, Tibet. It can be used to treat joint pain, leg pain and back pain. In addition, it is believed by the people to have the effects of aiding digestion, clearing heat and moistening the throat, and promoting the production of body fluids and quenching thirst. Kedi Lao also contains crude protein, crude fat, reducing sugar, non-reducing sugar, vitamins and other ingredients, and has good nutritional value.

[0004] There is no report on the effect of kerilao extract in relieving and treating asthma. Therefore, it is necessary to conduct further research on kerilao extract, which is of great significance for exploring safe and effective new drugs to control and treat allergic asthma. Summary of the invention

[0005] In order to overcome the above technical defects, the present invention uses Kedi Lao as the research object, conducts chemical and biological activity research on its extract, and finds that Kedi Lao extract has the effect of relieving and treating asthma and has good medicinal and edible value.

[0006] One of the purposes of the present invention is to provide the use of kerala or kerala extract in the preparation of a medicament for preventing, relieving and / or treating allergic asthma.

[0007] The following applications are also within the scope of protection of the present invention:

[0008] Furthermore, the kedirao extract is obtained by extracting kedirao with an extraction solvent; the extraction solvent is selected from one or more of water, methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, methyl formate, ethyl formate, methyl acetate, ethyl acetate, dichloromethane, chloroform, carbon tetrachloride, dichloroethane, acetone, butanone, and pentanone.

[0009] Furthermore, the kedirao extract is a kedirao water extract or a kedirao alcohol extract.

[0010] Furthermore, the water extract of Kedi Lao is an extract obtained by heating and refluxing Kedi Lao and water.

[0011] Furthermore, the kedi lao extract is prepared by the following steps:

[0012] S1. Take the Kedi Lao medicinal material, crush it, add the extraction solvent, and reflux extract it once or multiple times;

[0013] S2. Filtration, if multiple heating reflux extractions are performed, the filtrates are combined;

[0014] S3. The filtrate is concentrated to a viscous state to obtain a viscous product;

[0015] Preferably, the method further comprises the following steps:

[0016] S4. Drying the viscous product to obtain a dry product.

[0017] Furthermore, the drug's mechanism of action is manifested in the reduction of IL-4, IL-5, and IL-13 in bronchoalveolar lavage fluid, and the promotion of the increase of INF-γ.

[0018] Furthermore, the drug action mechanism is manifested as a decrease in IgE and OVA-IgE in serum.

[0019] Furthermore, the application concentration of the kerala extract is 0.1-500 mg / kg, for example 50-500 mg / kg, or 100-500 mg / kg, or 150-500 mg / kg, or 200-500 mg / kg, or 250-500 mg / kg.

[0020] Another object of the present invention is to provide a pharmaceutical composition comprising the Kedi Lao extract as an active ingredient and pharmaceutically acceptable excipients.

[0021] Furthermore, the Kedi Lao extract (such as Kedi Lao water extract or Kedi Lao ethanol extract) is the only active ingredient.

[0022] Furthermore, the pharmaceutical composition provided by the present invention can be used in combination with other components having anti-inflammatory activity.

[0023] In particular, the pharmaceutically acceptable carriers are generally recognized for this purpose and serve as inactive ingredients of medicaments.

[0024] The carrier includes excipients, such as starch, water, etc.; lubricants, such as magnesium stearate, etc.; disintegrants, such as microcrystalline cellulose, etc.; fillers, such as lactose, etc.; binders, such as pregelatinized starch, dextrin, etc.; sweeteners; antioxidants; preservatives; flavoring agents; spices, etc.

[0025] The medicine is in the form of tablets, capsules, pills, powders, granules, syrups, solutions, emulsions, injections, sprays, aerosols, and patches.

[0026] Wherein, the drug is administered via gastrointestinal and parenteral routes.

[0027] Particularly, the non-gastrointestinal administration route is selected from injection, respiratory tract administration, skin administration, mucosal administration or cavity administration.

[0028] Among them, the parenteral preparation is selected from injections, sprays, aerosols, patches and the like.

[0029] Particularly, the gastrointestinal administration preparation is selected from tablets, capsules, powders, granules, pills, solutions, emulsions or syrups.

[0030] The pharmaceutical composition of the present invention contains 0.1-90% by weight of active ingredients.

[0031] The pharmaceutical composition can be prepared according to methods known in the art. When used for this purpose, if necessary, the active ingredient can be combined with one or more solid or liquid pharmaceutical excipients and / or adjuvants to prepare a suitable administration form or dosage form for human use.

[0032] In addition, if necessary, colorants, preservatives, perfumes, flavoring agents, sweeteners or other materials may be added to the pharmaceutical preparations.

[0033] The dosage of the pharmaceutical composition of the present invention depends on many factors, such as the nature and severity of the allergic asthma to be prevented or treated, the sex, age, weight and individual response of the patient or animal, the route of administration and the number of administrations, etc. The above dosage can be administered in a single dosage form or divided into several, such as two, three or four dosage forms. The dosage level must be selected based on the specific route of administration, the severity of the condition to be treated, and the condition and previous medical history of the patient to be treated. However, the practice in the art is to start the dosage from a level lower than that required to obtain the desired therapeutic effect and gradually increase the dosage until the desired effect is obtained.

[0034] However, it should be recognized that the total daily dosage of the pharmaceutical composition of the present invention must be determined by the attending physician within the scope of sound medical judgment. For any particular patient, the specific therapeutically effective dosage level must be determined based on a variety of factors, including the disorder being treated and the severity of the disorder; the specific composition used; the patient's age, weight, general health, sex and diet; administration time, route of administration and excretion rate; duration of treatment; drugs used in combination or concurrently; and similar factors known in the medical field. For example, it is practiced in the art to start the administration of a dose lower than the level required to obtain the desired therapeutic effect and gradually increase the dose until the desired effect is obtained.

[0035] Generally speaking, the pharmaceutical composition of the present invention is calculated as the dosage for mammals, especially mice, based on the active ingredient.

[0036] The amount may be between 1-1000 mg / kg body weight / day, such as between 1-500 mg / kg body weight / day, such as between 50-500 mg / kg body weight / day, or 100-500 mg / kg, or 150-500 mg / kg, or 200-500 mg / kg, or 250-500 mg / kg.

[0037] The present invention discloses for the first time the medical use of Kedi Lao extract for preventing, relieving and / or treating allergic asthma. Kedi Lao extract can reduce inflammatory cell infiltration, improve airway structural damage, improve airway wall thickening; increase Th1 cytokine secretion, reduce Th2 cytokine secretion, and has a significant effect in relieving asthma. Compared with existing drugs for treating asthma, the Kedi Lao extract of the present invention is safer, more effective, milder and more durable, and has a multi-target and multi-effect mechanism of action, and will not produce strong drug resistance like single-target drugs. Therefore, Kedi Lao extract has considerable development and utilization value in relieving and treating allergic asthma. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 The effect of the Kedi Lao extract of the present invention on the lung pathology of OVA asthma mice;

[0039] Figure 2 The effect of the Kedi Lao extract of the present invention on the immunoglobulin in the serum of OVA asthma mice;

[0040] In the figure, ##P<0.01 compared with NC; **P<0.01 compared with MOD)

[0041] Figure 3 The figure shows the effect of the Kedi Lao extract of the present invention on inflammatory factors in bronchoalveolar lavage fluid (BALF) of OVA asthmatic mice; compared with NC, ##P<0.01; compared with MOD, **P<0.01). DETAILED DESCRIPTION

[0042] In order to make those skilled in the art better understand the technical scheme of the present invention, the present invention is described in detail below in conjunction with specific embodiments. The experimental methods for which specific conditions are not indicated in the following examples are usually carried out under normal conditions or according to the conditions recommended by the manufacturer. The test materials used in the following examples, unless otherwise specified, are purchased from conventional biochemical reagent stores. Unless otherwise specified, percentages and parts are calculated by weight. Unless otherwise defined, all professional and scientific terms used in the text have the same meaning as those familiar to those skilled in the art. In addition, any method and material similar to or equal to the recorded content can all be applied to the present invention. The preferred implementation methods and materials described in the text are only for demonstration purposes.

[0043] The endpoints and any values ​​of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0044] The kediolao selected by the invention is the ripe fruit of Elaeocarpus braceanus Watt exC.B.Clarke., a plant of the Elaeocarpus family. The fruit is extracted after the core is removed. The obtained kediolao extract reduces the secretion of IL-4, IL-5 and IL-13 in bronchoalveolar lavage fluid (BALF), promotes the secretion of INF-γ, and reduces the content of IgE and OVA-IgE in serum. The kediolao extract can be used as an active component for preparing a drug for preventing, relieving and / or treating allergic asthma.

[0045] Based on the present invention, the Kedi Lao extract is a Kedi Lao water extract or a Kedi Lao ethanol extract.

[0046] Based on the present invention, the water extract of Kedi Lao is an extract obtained by heating and refluxing Kedi Lao and water.

[0047] Based on the present invention, the kedi lao water extract is prepared by the following steps:

[0048] S1. Take the Kedi Lao medicinal material, crush it, add 8-10 times the amount of water, and reflux extract once or multiple times;

[0049] S2. Filtration, if multiple heating reflux extractions are performed, the filtrates are combined;

[0050] S3. The filtrate is concentrated to a viscous state to obtain a viscous product;

[0051] In a preferred embodiment, the following steps are also included:

[0052] S4. Drying the viscous product to obtain a dry product.

[0053] In some specific embodiments, the ratio of keratin to water is 1 g: 5-20 mL, and the extraction is performed by heating under reflux for one or more times (e.g., 2 times, 3 times, 4 times, or 5 times);

[0054] In some preferred embodiments, the ratio of keratin to water is 1g:5-15mL, 1g:8-10ml, 1g:8ml, 1g:9ml, 1g:10ml.

[0055] In some preferred embodiments, the heating reflux extraction time is 0.1-5h, 0.2-4h, 0.3-3h, 0.2-2h, 0.5-1.5h, 0.8-1.2h.

[0056] Based on the present invention, the kedirao ethanol extract is an extract obtained by heating and refluxing extraction of kedirao and ethanol or an ethanol solution.

[0057] Based on the present invention, the ethanol extract of Kedelao is an extract obtained by heating and refluxing Kedelao with ethanol or an ethanol solution.

[0058] The kedi lao ethanol extract is prepared by a method comprising the following steps:

[0059] S1. Kedi Lao is mixed with ethanol or 10%-90% ethanol solution in a ratio of 1 g: 5-20 mL, and heated under reflux for extraction once or multiple times (e.g., 2 times, 3 times, 4 times or 5 times);

[0060] S2. Filtration, if multiple heating reflux extractions are performed, the filtrates are combined;

[0061] S3. The filtrate is concentrated to a viscous state to obtain a viscous product;

[0062] In a preferred embodiment, the following steps are also included:

[0063] S4. Drying the viscous product to obtain a dry product.

[0064] In some specific embodiments, the ethanol solution is 20%-80% ethanol solution, 30%-70% ethanol solution, 40%-70% ethanol solution, 50%-70% ethanol solution, 55%-65% ethanol solution or 50% ethanol solution.

[0065] In some specific embodiments, the ratio of keratin to ethanol or ethanol solution is 1 g: (5-20) ml, and the extraction is performed by heating and refluxing once or multiple times (e.g., 2 times, 3 times, 4 times or 5 times).

[0066] In some preferred embodiments, the ratio of keratinase to ethanol solution is 1g:5-15mL, 1g:8-10ml, 1g:8mL, 1g:9mL, 1g:10mL.

[0067] In some preferred embodiments, before heating to reflux, the ethanol extract of Kedi Lao is defatted with petroleum ether or not.

[0068] In some specific embodiments, the heating reflux extraction time is 0.1-5h, 0.2-4h, 0.3-3h, 0.2-2h, 0.5-1.5h, 0.8-1.2h.

[0069] In some specific embodiments, the concentration is rotary evaporation concentration, and after concentration to a certain volume, reduced pressure vacuum drying is performed, the drying temperature is 40-60° C., and the time is 40-60 h.

[0070] All experimental data in the following embodiments and experimental examples were statistically analyzed using SPSS 20.0 statistical software, and the experimental data were expressed as mean ± standard deviation (x ± s), and the inter-group comparison was performed using the t test (the t test was used when the variances were equal, and the t' test was used when the variances were unequal). The test results were considered statistically significant when P < 0.05.

[0071] The technical solution of the present invention is further described in detail below in conjunction with specific embodiments and drawings. It should be understood that the following embodiments are only used to explain the present invention and are not used to limit the present invention.

[0072] Example 1 Preparation of Kedi Lao Extract

[0073] Take 1000g of fresh Kedirao, sort, wash, remove the core and then crush, according to the ratio of Kedirao to ethanol solution of 1g:10ml, mix the Kedirao powder and 50% ethanol solution, soak for 1h, reflux extraction 2-3 times, each reflux extraction time is 1.5h, combine the filtrates of the two extractions, concentrate by rotary evaporation until viscous, dry at 50-60℃ for 40-60h, and obtain the Kedirao extract for use.

[0074] Example 2 Investigating the effect of Kedi Lao extract on lung tissue of allergic asthma mice

[0075] Preparation and grouping of allergic asthma mouse model: BALB / c mice were fed adaptively for 7 days. One week later, they were randomly divided into 5 groups: normal group (NC), model group (MOD), positive drug group (DEX), high-dose drug group EA-H (500 mg / kg), and low-dose drug group EA-L (250 mg / kg), with 6 mice in each normal and model group and 6 mice in each drug group.

[0076] After the mice were grouped, the model was established. Except for the NC group, which was injected with 0.2 ml of normal saline intraperitoneally, the other four groups were sensitized by intraperitoneal injection of 0.2 ml of 1 mg / ml ovalbumin (OVA, Sigma-Aldrich, St. Louis, MO, USA) and 5 mg / ml aluminum hydroxide (Al(OH)3, Sigma-Aldrich, St. Louis, MO, USA) mixed sensitization solution on days 1, 8 and 15. On days 21-27, 1% OVA provocation solution was used for 30 minutes of nebulization. Normal saline was used instead of nebulization in the normal group. After 30 minutes of nebulization, the drug was administered by gavage, with a volume of 0.1 ml / 10 g. The drug dosages were as follows: the NC and MOD groups were given normal saline, the DEX group was given Dex: 1.0 mg / kg (Sigma-Aldrich, St. Louis, MO, USA), the EA-H group was given elao extract (EA): 500 mg / kg, and the EA-L group was given elao extract (EA): 250 mg / kg.

[0077] Serum sample collection: Samples were collected on the 28th day of modeling. After the mice were anesthetized, their whiskers were trimmed, and blood was collected from their eyeballs (dropped in midair to avoid hemolysis). The blood was collected in a 1.5 mL centrifuge tube and placed at room temperature for 1 hour. The tube was centrifuged in a low-temperature centrifuge (centrifugation conditions: 4°C, 3000 rpm, 15 min), and the supernatant was aliquoted and stored in a -80°C refrigerator.

[0078] Bronchoalveolar lavage fluid (BALF): 24 h after the last OVA aerosolization, the mice were eyeballed and blood was collected. The mice were then killed by cervical dislocation. The right lung of the mice was ligated after thoracotomy. 0.6 mL of sterile PBS was used to lavage the left lung of the mice. Each mouse was lavaged 3 times. The lavage fluid was collected and mixed, and centrifuged at 3000 rpm for 10 min at 4°C. The supernatant was aliquoted and stored at -80°C.

[0079] Lung tissue pathological examination: 24 hours after the last OVA aerosolization, the mice were eyeballed and blood was collected. Then, the mice were killed by cervical dislocation. The right middle lobe of the lung was taken out by opening the chest cavity and fixed in 4% paraformaldehyde, embedded in paraffin, and 5 μm thick lung tissue sections were cut. After dewaxing, PAS staining and HE staining were performed, and the pathological conditions of the lung tissue were observed under a microscope (such as Figure 1 shown).

[0080] like Figure 1 As shown in the figure, compared with the normal group (NC), a large number of inflammatory cells infiltrated around the trachea and blood vessels in the model group (MOD) mice, and the airway and blood vessel walls were significantly thickened. Compared with the MOD group, the inflammatory cell infiltration of the trachea in the lungs of the mice in the DEX group, EA-L and EA-H groups was significantly improved, indicating that the positive drugs dexamethasone and keratinase high and low dose groups can relieve airway inflammation and play a role in treating allergic asthma.

[0081] Example 3 Investigating the effect of Kedi Lao extract on serum Ig-E and OVA-IgE levels

[0082] The experiment was carried out according to the operating method of the ELISA kit, which was divided into 9 steps: dilution of the standard, sample incubation, addition of detection antibody, plate washing, enzyme incubation, plate washing, color development, termination and microplate reader determination. The levels of Ig-E and OVA-IgE in mouse serum were determined (such as Figure 2 shown).

[0083] from Figure 2 It can be seen that compared with the normal control group, the levels of tIgE and OVA-IgE in the model control group mice were significantly increased (##p<0.01); compared with the model control group, the positive drug (dexamethasone) and high and low doses of clematis extract can reduce the levels of tIgE and OVA-IgE in serum, and there are significant differences (**p<0.01).

[0084] Example 4 Investigating the effect of Kedi Lao extract on the level of inflammatory factors

[0085] The experiment was carried out according to the operating method of the ELISA kit, which was divided into 9 steps: dilution of the standard, sample incubation, addition of detection antibody, plate washing, enzyme incubation, plate washing, color development, termination and microplate reader determination. The levels of INF-γ, IL-13, IL-4 and IL-5 inflammatory factors in the bronchoalveolar lavage fluid of mice were determined (such as Figure 3 shown).

[0086] The results are as follows Figure 3 As shown in the figure, compared with the NC group, the INF-γ in the BALF of the mice in the MOD group was decreased (##P<0.01); the contents of IL-13, IL-4, and IL-5 were significantly increased (**p<0.01). Compared with the MOD group, the INF-γ in the BALF of the mice in the DEX group and the EA-H group was significantly increased (**p<0.01); the contents of IL-13, IL-4, and IL-5 in the BALF of the mice in the DEX group, the EA-L group, and the EA-H group were significantly decreased (**p<0.01), indicating that the positive drugs dexamethasone and kerdilao at low and high doses can reduce the level of inflammatory factors in the bronchoalveolar lavage fluid. Among them, the high dose of kerdilao extract has a better effect than the low dose.

[0087] IgE is a type of immunoglobulin. The entire process of asthma pathophysiology is significantly related to the increase of IgE in circulating blood. In the asthma modeling process of the present invention, the drug intervention group can significantly reduce the Ig-E content in circulating blood, thereby preventing IgE from binding to the high-affinity receptors of mast cells and basophils, thereby avoiding the release of mediators after contact with allergens; reducing the survival of basophils and mast cells; preventing allergic reactions promoted by IgE; reducing the release of IL-4 and IL-5, and other effects on alleviating asthma.

[0088] IL-13, IL-4, and IL-5 can promote Th2 cell differentiation, eosinophil infiltration, mast cell proliferation, goblet cell metaplasia, mucus hypersecretion and airway remodeling, upregulation of IgE, and other processes that aggravate asthma, and play a vital role in the pathogenesis of asthma. In the asthma modeling process described in this description, drugs can reduce inflammation and relieve asthma by inhibiting the relative expression of IL-13, IL-4, and IL-5.

[0089] INF-γ can induce host cells to produce antiviral proteins, and it can also enhance the expression of MHC class I molecules, making virus-infected cells more easily recognized and eliminated by cytotoxic T lymphocytes (CTLs). In the asthma modeling process of the present invention, the drug can reduce inflammation and relieve asthma by increasing the relative expression of INF-γ.

[0090] It can be seen from the results that the Kedi Lao extract provided by the present invention can effectively prevent allergic asthma.

[0091] Finally, it should be noted that the above description is only a preferred embodiment of the present invention. Under the guidance of the present invention, those skilled in the art can make a variety of similar expressions without violating the purpose and claims of the present invention, and such changes all fall within the protection scope of the present invention.

Claims

1. Use of kedirao or kedirao extract in preparing medicine for preventing, alleviating and / or treating allergic asthma.

2. The use according to claim 1, characterized in that: The kedeluo extract is obtained by extracting kedeluo with an extraction solvent; the extraction solvent is selected from one or more of water, methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, methyl formate, ethyl formate, methyl acetate, ethyl acetate, dichloromethane, chloroform, carbon tetrachloride, dichloroethane, acetone, butanone, and pentanone.

3. The use according to claim 2, characterized in that: The Kedi Lao water extract is a water extract or a Kedi Lao alcohol extract.

4. The use according to claim 2, characterized in that: The kediola extract is prepared by the following steps: S1. Take the Kedi Lao medicinal material, crush it, add the extraction solvent, and reflux extract it once or multiple times; S2. Filtration, if multiple heating reflux extractions are performed, the filtrates are combined; S3. The filtrate is concentrated to a viscous state to obtain a viscous product; Preferably, the method further comprises the following steps: S4. Drying the viscous product to obtain a dry product.

5. The use according to any one of claims 1 to 4, characterized in that: The drug action mechanism is manifested in the reduction of IL-4, IL-5, and IL-13 in the alveolar lavage fluid, and the promotion of the increase of INF-γ.

6. The use according to any one of claims 1 to 4, characterized in that: The drug action mechanism is manifested as the reduction of IgE and OVA-IgE in serum.

7. The use according to any one of claims 1 to 4, characterized in that: The application concentration of the kediola extract is 1-500 mg / kg, for example 50-500 mg / kg, or 100-500 mg / kg, or 150-500 mg / kg, or 200-500 mg / kg, or 250-500 mg / kg.

8. A pharmaceutical composition, characterized in that The invention comprises a kediola extract as an active ingredient and pharmaceutically acceptable auxiliary materials.

9. The pharmaceutical composition according to claim 8, characterized in that The kediola extract is the kediola extract described in any one of claims 2-4.

10. The pharmaceutical composition according to claim 7, characterized in that Other components having anti-inflammatory activity are also included.

Images